NCT03796377 is a Phase 1 clinical trial of St Johns Wort Extract in Drug Interaction Study, sponsored by Insel Gruppe AG, University Hospital Bern.

Who is sponsoring NCT03796377?

NCT03796377 is sponsored by Insel Gruppe AG, University Hospital Bern.

What drugs are being tested in NCT03796377?

Interventions in NCT03796377: St Johns Wort Extract, Rivaroxaban.

What condition does NCT03796377 study?

NCT03796377 studies Drug Interaction Study.

Is NCT03796377 still recruiting?

NCT03796377 is currently completed. Last updated 3 November 2020.

Last reviewed 2020-11-03 · How we verify

NCT03796377

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Rivaroxaban Hypericum Trial

Completed Phase 1 Last updated 3 November 2020

What this trial tests

Phase 1 trial testing St Johns Wort Extract in Drug Interaction Study in 12 participants. Completed in 9 April 2019.

Timeline

13 February 2019

Primary endpoint
9 April 2019

9 April 2019

Quick facts

Lead sponsor	Insel Gruppe AG, University Hospital Bern
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	other
Enrollment	12
Start date	13 February 2019
Primary completion	9 April 2019
Estimated completion	9 April 2019
Sites	1 location across Switzerland

Drugs / interventions tested

St Johns Wort Extract — full drug profile →
Rivaroxaban (rivaroxaban) — full drug profile →

Conditions studied

Drug Interaction Study — all drugs for Drug Interaction Study →

Sponsor

Insel Gruppe AG, University Hospital Bern

Who can join

Adults 18 to 45, any sex, with Drug Interaction Study. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Single-center, open-label, sequential treatment study to investigate the influence of the combined P-glycoprotein and CYP3A4 inducer hypericum perforatum on the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy volunteers.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Insel Gruppe AG, University Hospital Bern trials

Trials by the same sponsor.

NCT06546384 — GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease · NA · not yet recruiting
NCT07524049 — Giving Children a Voice in Paediatric Anaesthesia · not yet recruiting
NCT07415668 — Motor Eloquent Navigated Transcranial Magnetic Stimulation for Radiosurgery Planning · NA · not yet recruiting
NCT07478536 — Stockholm3 Test Validation in Men on Active Surveillance in Switzerland (CHAS3 Trial) · not yet recruiting
NCT07201506 — Real-Time Intracardiac Echocardiography for Ventricular Arrhythmia Ablation · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03796377 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Insel Gruppe AG, University Hospital Bern
Last refreshed: 3 November 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03796377.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing